Research Studies

"Providence Health Care Research Institute is an academic teaching hospital affiliated with the University of British Columbia and Simon Fraser University. As a continuous learning organization, we pursue real life health solutions to challenges that directly impact the health of our patients."
- Providence Health Care Research Institute

Respiratory Therapists actively participate in conducting and gathering information for studies that directly impact our patients.  New studies are starting all the time.  Please see the list below for some of the studies we are currently working on.


A Prospective Safety and Feasibility Study of the RejuvenAir™ System Metered Cryospray Therapy for Chronic Bronchitis Patients.

Summary: The RejuvenAir™ System, a procedure that uses liquid nitrogen to promote healthy lung tissue growth, is being tested with patients diagnosed with symptomatic Chronic Bronchitis.
Principal Investigator (PI): Dr. Don Sin

A Feasibility Study: A Safety Evaluation of the Gala Airway Treatment System on Patients with Chronic Bronchitis in Canada.

Summary: The Gala Airway Treatment System utilizes electrical energy technology to reduce hypersecretion in the bronchi to improve symptoms related to Chronic Bronchitis.
Principal Investigator (PI): Dr. Delbert R. Dorscheid

Prospective, randomized, placebo controlled trial of the efficacy and safety of inhaled nitric oxide (NO) in cystif fibrosis (CF) Patient.

Summary: To evaluate the treatment of baterial infections in patients with Cystic Fibrosis using Nitric Oxide.
Principal Investigator (PI): Dr. Bradley Quon

A randomized, double-­blind, placebo-­controlled study to evaluate the efficacy and safety of dupilumab in patients with severe dependent asthma.

Summary: Understanding the saftey and effectiveness of the drug Dupilumab in the treatment of severe steroid dependent asthma.
Principal Investigator (PI): Dr. Delbert R. Dorscheid

Multicenter, international, double blind, 2-­arm, randomized, placebo-­controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD.

Summary: The drug Pirfenidone is being tested as the use for an antibiotic and anti-­inflammatory for people with Unclassified Interstitial Lung Disease.
Principal Investigator (PI): Dr. Chris Ryerson

A Phase 2, Randomized, Double-­blind, Controlled Study to Evaluate the Safety and Efficacy of VX-­440 Monotherapy and Combination Therapy in Subjects Aged 12 Years and Older with Cystic Fibrosis.

Summary: Testing the long term safety and effects for the combined use of  VX-­440, tezacaftor and ivacaftor in patients with Cystic Fibrosis to increase the function and production of the CFTR gene.
Principal Investigator (PI): Dr. Bradley Quon

A Phase 3, Open-­label, Rollover Study to Evaluate the Safety and Efficacy of Long-­term Treatment WithVX-­661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-­CFTR Mutation. 

Summary: Evaluating the long term safety and effects for the combined use of VX-­661 and ivacaftor for improving the CFTR gene in patients with Cystic Fibrosis.
Principal Investigator (PI): Dr. Bradley Quon

Patients, please speak with your respirologist to see if you qualify for any of these studies. If you have been told by your doctor that you have a respiratory disease, you may also contact the Research Centre staff at (604) 806-9485 or (604)-806-8117 for more information.